

QIBA fMRI Biomarker Committee (BC) Meeting

Wednesday, February 1, 2023, at 11 a.m. (CT)

Meeting Summary

In attendance

Jay Pillai, MD (Co-chair)

David Soltysik, PhD (Co-chair)

Shruti Agarwal, PhD

Andrew Kalnin, MD

Erin Kelly, PhD

Anthony Liu, PhD

James Voyvodic, PhD

Yuxiang Zhou, PhD, DABR

RSNA staff

Susan Stanfa

Review of Previous Meeting Summary:

- The 01.18.2023 meeting summary was approved as presented

Topics Discussed:

- Process of selecting clusters for comparison
- Review of Claim
- Section 4: Assessment Procedures

Next Steps / Action Items:

- Discussion regarding whether Claim needs to be refined
- A better explanation for the method to determine which clusters need to be repeated in a second scan needs to be added to Section 4: Assessment Procedures
 - Concern regarding Claim and pairing location of clusters in an activation map
 - Dr. Voyvodic to recalculate reproducibility measurements for the following cluster criteria: (1) largest in size, (2) closest to anatomical landmarks, and (3) strongest activation
 - Dr. Voyvodic to redo the cluster reproducibility plots in three ways, based on: (1) average cluster, (2) largest cluster, (3) strongest cluster; then, frequency that the strongest or largest actually agree with the closest one will be determined
 - Dr. Voyvodic will also try to find the two anatomical locations that Dr. Kalnin pointed out on an atlas, and consider using that as a fourth criterion
 - Once the fMRI BC decides how to identify which cluster is fundamental to the Claim, Dr. Voyvodic will draft the explanatory text
- Next steps following completion of the Profile:
 - Circulation for full BC review and a vote-to-release for Stage 1: Public Comment
 - MR CC vote-to-release will follow

Next meeting: Wednesday, February 15, 2023, at 11 a.m. CT (1st & 3rd weeks of each month)

Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected in meeting summaries.